Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
6(75.0%)
Phase 2
2(25.0%)
8Total
Phase 1(6)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT01129193Phase 1Completed

AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma

Role: collaborator

NCT02052128Phase 1Unknown

Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers

Role: lead

NCT02049190Phase 1Unknown

Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

Role: lead

NCT01124539Phase 2Unknown

Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma

Role: lead

NCT00956787Phase 2Unknown

Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)

Role: lead

NCT00978523Phase 1Completed

Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma

Role: lead

NCT01202370Phase 1Completed

A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies

Role: collaborator

NCT00389480Phase 1Completed

Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies

Role: lead

All 8 trials loaded